Pain Relief vs Addiction: Will Vertex’s non-opioid (hopefully nonaddictive) Suzetrigine/VX-548 be FDA-approved in 2024?
Mini
3
Ṁ17Jan 5
58%
chance
1D
1W
1M
ALL
Resolution source:
From Wikipedia:
Vertex announced in January 2024 that VX-548 successfully met several enpoints in its Phase III trials. The drug relieved moderate to severe post-surgical pain. Vertex hopes the drug, which operates on peripheral nerves, will avoid the addictive potential of opioids. There are many other small molecule sodium channel blocker candidates.
Independence:
I will not take positions related to this question on any market sites.
Get Ṁ1,000 play money
Related questions
Related questions
Will AOH1996 be FDA approved before 2040?
44% chance
Will a drug to be used by most healthy adults be approved by 2043 year end?
66% chance
Will Scott Alexander endorse a Delta-Opioid-Agonist antidepressant before 2029?
58% chance
Will a drug that didn't go through human clinical trials be approved by 2034?
29% chance
Will an AI-designed drug get FDA approval by the end of 2025?
30% chance
Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?
66% chance
Will the FDA approve a drug to prevent migraine headaches by 2025?
66% chance
Will Pfizer announce a weight loss drug competing with Ozempic and Wygovy before 12/31/2024?
43% chance
Will Retatrutide (new obesity drug) be FDA approved by the end of 2025?
46% chance
Will any country legalize recreational use of opioids before 2045?
57% chance